| P2093 | author name string | Takeshi Miyamoto | |
| P2860 | cites work | Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation | Q69373333 |
| | Effect of cytokine treatment (granulocyte colony-stimulating factor and stem cell factor) on hematopoiesis and the circulating pool of hematopoietic stem cells in mice | Q71118370 |
| | Characterization of peripheral blood stem cells in mice | Q71228735 |
| | Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow | Q71249427 |
| | Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor | Q72075255 |
| | An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand | Q73281247 |
| | Hematopoietic stem cell quiescence maintained by p21cip1/waf1 | Q73532192 |
| | The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats | Q73826959 |
| | Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation | Q74411385 |
| | Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization | Q77459339 |
| | Osteoclasts eat stem cells out of house and home | Q83948512 |
| | Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure | Q84346511 |
| | Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study | Q84553314 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 |
| | Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis | Q24324701 |
| | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 |
| | Concise review: multiple niches for hematopoietic stem cell regulations | Q27693739 |
| | Bone resorption by osteoclasts | Q28145169 |
| | Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche | Q28505006 |
| | DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells | Q28506839 |
| | TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Osteoclast differentiation and activation | Q29547556 |
| | SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells | Q29615006 |
| | Osteoblastic cells regulate the haematopoietic stem cell niche | Q29615007 |
| | Identification of the haematopoietic stem cell niche and control of the niche size | Q29615008 |
| | Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches | Q29617460 |
| | The bone marrow at the crossroads of blood and immunity | Q33581299 |
| | The cell biology of osteoclast function. | Q33819720 |
| | Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo | Q34153374 |
| | Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure | Q34216753 |
| | Reconstructing the skeleton with intermittent parathyroid hormone | Q34336914 |
| | Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group | Q34409983 |
| | Characterization of structural domains of human osteoclastogenesis inhibitory factor | Q34457751 |
| | Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 |
| | Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow | Q34488568 |
| | Stem cells and their niches | Q34507142 |
| | Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin | Q42930218 |
| | Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. | Q43038398 |
| | Mice lacking c-fos have normal hematopoietic stem cells but exhibit altered B-cell differentiation due to an impaired bone marrow environment | Q43181439 |
| | Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density | Q43252754 |
| | Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. | Q43606336 |
| | Bifurcation of osteoclasts and dendritic cells from common progenitors | Q43757343 |
| | Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis | Q44956032 |
| | Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. | Q45154679 |
| | Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo | Q46277067 |
| | Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. | Q46459616 |
| | Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor | Q46764348 |
| | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 |
| | Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group | Q48527134 |
| | Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. | Q51747454 |
| | Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. | Q51803777 |
| | Foxo3a is essential for maintenance of the hematopoietic stem cell pool. | Q51960990 |
| | Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 |
| | Peripheral blood progenitor cells mobilized by recombinant human granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by ser | Q52208849 |
| | Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. | Q52215640 |
| | Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential | Q52222892 |
| | Role of osteoclasts in the hematopoietic stem cell niche formation. | Q53169307 |
| | Efficient retrovirus transduction of mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor | Q54197236 |
| | Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. | Q54415335 |
| | Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial | Q57752107 |
| | c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 |
| | The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene | Q59092154 |
| | Calcitonin receptor antibodies in the identification of osteoclasts | Q60601212 |
| | Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappa B ligand on adult T-cell leukemia cells | Q63384151 |
| | The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats | Q67923874 |
| | Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression | Q34640861 |
| | Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics | Q35098268 |
| | Differentiation and function of osteoclasts | Q35113943 |
| | Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts | Q35378487 |
| | Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization | Q35441456 |
| | Mobilization of hematopoietic stem cells from the bone marrow niche to the blood compartment | Q35579264 |
| | Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow | Q35826041 |
| | Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche | Q35976918 |
| | Molecular and cellular mechanisms of the anabolic effect of intermittent PTH | Q36016775 |
| | Hematopoietic stem cells and their niche. | Q36175339 |
| | FGF signaling facilitates postinjury recovery of mouse hematopoietic system. | Q36206420 |
| | Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors | Q36375584 |
| | Nervous activity in a stem cell niche | Q36378533 |
| | Bone-marrow haematopoietic-stem-cell niches | Q36402226 |
| | Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size | Q36403763 |
| | TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. | Q36404187 |
| | The hematopoietic stem cell in its place | Q36426799 |
| | The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization | Q36624070 |
| | Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure | Q36625603 |
| | Hematopoietic stem cell mobilization: updated conceptual renditions | Q36912472 |
| | The hematopoietic stem cell and its niche: a comparative view | Q37023125 |
| | Uncertainty in the niches that maintain haematopoietic stem cells | Q37103620 |
| | The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization | Q37791426 |
| | Minireview: The stem cell next door: skeletal and hematopoietic stem cell "niches" in bone | Q37879322 |
| | In and out of the niche: perspectives in mobilization of hematopoietic stem cells | Q37882082 |
| | New targets for intervention in the treatment of postmenopausal osteoporosis | Q37935523 |
| | Denosumab in patients with cancer-a surgical strike against the osteoclast | Q37974570 |
| | The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction | Q38029394 |
| | Hematopoietic stem cell fate decisions are regulated by Wnt antagonists: comparisons and current controversies | Q38047612 |
| | A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization | Q38321018 |
| | Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 |
| | Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. | Q39997716 |
| | Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells | Q40277201 |
| | Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. | Q40786200 |
| | Differentiation and proliferation of hematopoietic stem cells | Q40910117 |
| | Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 |
| | CD45 regulates retention, motility, and numbers of hematopoietic progenitors, and affects osteoclast remodeling of metaphyseal trabecules | Q42135720 |
| | Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. | Q42648818 |
| P433 | issue | 4 | |
| P304 | page(s) | 198-206 | |
| P577 | publication date | 2013-10-18 | |
| P1433 | published in | World journal of orthopedics | Q27724018 |
| P1476 | title | Role of osteoclasts in regulating hematopoietic stem and progenitor cells | |
| P478 | volume | 4 | |